CB1-SSi Platform Aelis Farma has a proprietary signaling-specific CB1 inhibitor platform that opens a first-in-pharmacology approach for multiple brain diseases, creating collaboration opportunities through licensing or co-development of additional indications beyond cannabis use disorder and cognitive impairment. The platform's differentiation and emerging data position it as a compelling target for pharma partners seeking novel CNS therapies with potentially differentiated safety profiles.

Clinical Progress The company is advancing drug candidates in brain disorders with high unmet need, including cannabis use disorder and Down syndrome related cognitive deficits, offering partners data-driven milestones and readouts to anchor potential deal terms and value creation. Ongoing trials and upcoming study commencements provide opportunities for collaborative research and data sharing.

Strategic Partnerships Aelis Farma has a track record of collaboration with public funding bodies and research institutions, supported by strategic hires such as a Chief Corporate Development Officer, signaling a strong appetite for partnering, licensing, and funded development deals. This network and leadership can facilitate co-development, technology licensing, and access to European grant programs.

Clinical Networks Based in Bordeaux within the Inserm Magendie Neurocentre, the company can leverage established clinical and academic networks to accelerate patient recruitment, access to CNS expertise, and potential partnerships with European trial ecosystems for multi-center studies.

Investment Potential With a lean team and an early revenue profile, Aelis Farma presents a strategic entry point for risk-sharing deals, milestone payments, and potential royalties tied to program advancement, appealing to partners seeking high-value CNS opportunities in a validated platform.